Contact Us Today|info@empharmd.com

When the FDA Met #FOAMed

For a while now, there has been a lot of discussion among folks in the free open access medical education (FOAMed) community related to the acknowledgement and recognition in the academic realm. Recently, one major academic institution that has now set the stage for the recognition of FOAMed as scholarly activity for the purposes of promotion and tenure: The Mayo Clinic. This unprecedented move should surely serve as a stepping stone for other academic institutions [...]

By |2016-06-19T18:00:00-05:00June 19th, 2016|EM PharmD Blog|0 Comments

Replacement for Unused Alteplase (tPA)

A 78-year-old female with acute onset of right-sided weakness, facial droop, and slurred speech presents via ambulance to your emergency department (ED). After CT and labs are completed, the neurology team decides to administer alteplase (tPA) for acute ischemic stroke and the pharmacist begins reconstituting the medication. However, the family arrives and states they do not want the patient to receive tPA. What should you do with the reconstituted product that is now not to [...]

By |2016-06-13T10:00:00-05:00June 13th, 2016|EM PharmD Blog|0 Comments

Diltiazem IV to PO Explained

One of the oldest posts on EMPharmD has finally received an update. One of the most prominent lessons I've learned since graduating residency years ago is that the more I learn, the more I realize I do not know, and seeking out help is not a sign of weakness, but a strength.  Artist rendering of diltiazem formula investigationAs such, when I encountered a wall in trying to trace the origin of the diltiazem IV to PO [...]

By |2016-06-05T17:50:00-05:00June 5th, 2016|EM PharmD Blog|0 Comments